Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actuate 1801: 9-ING-41 in Refractory Cancers and Pancreatic Cancer
NCT03678883Phase 2Active, not recruiting
- Sponsor
- Actuate Therapeutics
- Start
- Jan 2019
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of elraglusib in Treatment-resistant cancer, pancreatic cancer (PC), solid tumor, hematologic malignancy, sponsored by Actuate Therapeutics. Started Jan 2019; status: active, not recruiting.
02
Drugs
elraglusib
03
Conditions
Treatment-resistant cancerpancreatic cancer (PC)solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT03678883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03678883.